{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T22:08:09Z","timestamp":1795039689616,"version":"4.10.2"},"reference-count":21,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2024,3,3]]},"DOI":"10.1080\/14712598.2024.2325551","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T02:52:10Z","timestamp":1709088730000},"page":"119-123","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":14,"title":["More failure with solanezumab \u2013 this time in preclinical Alzheimer\u2019s disease"],"prefix":"10.1080","volume":"24","author":[{"given":"Sheila A","family":"Doggrell","sequence":"first","affiliation":[{"name":"School of Pharmacy and Medical Sciences, Gold Coast Campus, Griffith University, Gold Coast, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,3,3]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2305032"},{"key":"e_1_3_3_4_1","unstructured":"ClinicalTrials. Gov clinical trial of solanezumab for older individuals who may be at risk of memory loss (A4). [cited 2023 Nov 19]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02008357?term=SOLANEZUMAB&rank=6"},{"key":"e_1_3_3_5_1","unstructured":"Mayo Clinic. Alzheimer\u2019s disease. [cited 2023 Dec 19]. Available from: https:\/\/www.mayoclinic.org\/diseases-conditions\/alzheimers-disease\/symptoms-causes\/syc-20350447"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.5582\/ddt.2023.01215"},{"key":"e_1_3_3_7_1","unstructured":"U.S. Food & Drug Administration. FDA grants accelerated approval for Alzheimer\u2019s drug. [cited 2023 Dec 19]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-alzheimers-drug"},{"key":"e_1_3_3_8_1","unstructured":"U.S. Food & Drug Administration. FDA converts novel Alzheimer\u2019s disease treatment to traditional approval. [cited 2023 Dec 19]. Available from: https:\/\/www.Fda.gov\/news-events\/press-announcements\/fda-converts-novel-alzheimers-disease-treatment-traditional-approval"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43933-5"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.09.224"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e3181cb577a"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1312889"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2015.06.1893"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705971"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2018.1543397"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13031"},{"key":"e_1_3_3_18_1","unstructured":"ClinicalTrials.gov A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer\u2019s Disease (ExpeditionPRO). [cited 2023 Dec 19]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02760602?intr=Solanezumab&rank=2"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awad159"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S325026"},{"key":"e_1_3_3_21_1","unstructured":"ClinicalTrials. Gov a study to evaluate safety and tolerability of aducanumab in participants with Alzheimer\u2019s disease who had Previously participated in the aducanumab studies 221AD103 221AD301 221AD302 and 221AD205. [cited 2023 Dec26]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04241068?term=aducanumab&rank=4#more-information"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.17219\/acem\/171379"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-023-01512-w"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2024.2325551","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T09:46:38Z","timestamp":1727171198000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2024.2325551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,3]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3,3]]}},"alternative-id":["10.1080\/14712598.2024.2325551"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2024.2325551","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-12-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}